Skip to main content
. 2020 Sep 23;12(10):2730. doi: 10.3390/cancers12102730

Figure 2.

Figure 2

Sorafenib resistance gene signatures—prognostic significance and drug repurposing candidates. (A) Percentage of primary tumor samples in The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) dataset containing the four sorafenib resistance gene signatures (SR+). (B) Kaplan–Meier plot of overall survival of TCGA LIHC patients with primary tumors harboring the Huh7-R-A7 SR gene signature (n = 181 SR+) and those with primary tumors containing the inverse SR gene signature (n = 190 SR-). Heatmap visualization of hierarchical clustering analysis of connectivity scores for LINCS drugs derived from gene expression profiles of (C) HCC cell lines (n = 18) from the CellMiner database and (D) HCC sorafenib resistance (SR) experimental models.